Pharmaceuticals: Major · attribution context sourced from stored price moves, stored event labels, and peer-relative residuals inside the XLV constituent company universe.
Review priority 78 · Source rank 0 · Volume 3.7x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.67% · Sector +0.05% · Industry +0.09% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -8.86%Review priority 78 · Source rank 0 · Volume 4.9x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.10% · Sector -0.02% · Industry -0.11% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -8.09%Review priority 78 · Source rank 0 · Volume 4.7x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.17% · Sector -1.17% · Industry -0.43% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -8.08%Review priority 78 · Source rank 0 · Volume 3.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.59% · Sector -0.92% · Industry -0.01% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -9.27%Review priority 76 · Source rank 0 · Volume 3.5x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.31% · Sector -0.04% · Industry +0.11% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +8.08%Review priority 76 · Source rank 0 · Volume 3.2x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.36% · Sector -0.23% · Industry +0.03% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -8.62%Review priority 74 · Source rank 0 · Volume 2.7x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.19% · Sector +0.14% · Industry -0.00% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +8.71%Review priority 68 · Source rank 0 · Volume 2.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.33% · Sector +1.40% · Industry +0.46% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +6.73%| Date | Label | Move | Residual after context | Scope | Confidence |
|---|---|---|---|---|---|
| Mar 13, 2020 | Broad market moved +8.28% with this stock | +8.56% | +7.31% | Macro | 58% |
| Apr 6, 2020 | Broad market moved +8.02% with this stock | +8.30% | +4.85% | Macro | 58% |
| Oct 29, 2024 | Incyte Corporation 10-Q: 10-Q | +12.04% | -0.18% | Direct | 70% |
| Oct 29, 2024 | Incyte Corporation 8-K: 8-K | +12.04% | -0.18% | Direct | 70% |
| Oct 29, 2024 | NASDAQ:INCY quarterly report filing | +12.04% | -0.18% | Direct | 94% |
| Jul 29, 2025 | Incyte Corporation 10-Q: 10-Q | +10.28% | +0.81% | Direct | 70% |
| Jul 29, 2025 | Incyte Corporation 8-K: 8-K | +10.28% | +0.81% | Direct | 70% |
| Jul 29, 2025 | NASDAQ:INCY quarterly report filing | +10.28% | +0.81% | Direct | 94% |
| May 13, 2024 | Incyte Corporation 8-K: FORM 8-K | +8.56% | +0.51% | Direct | 70% |
| May 13, 2024 | NASDAQ:INCY beneficial ownership filing | +8.56% | +0.51% | Direct | 94% |